title: Effects of ranibizumab on exudative disciform scars.
abstract: OBJECTIVE
  To evaluate the effect of intravitreal ranibizumab in patients with leaking disciform scars.
  
  
  METHODS
  In this retrospective case series, 31 eyes received one or two ranibizumab injections for treatment of choroidal neovascularization. Visual acuity, central retinal thickness, and macular volume were measured prior to injection and at 1-month follow-up.
  
  
  RESULTS
  After one injection (n = 31), mean optical coherence tomography (OCT) central foveal thickness decreased from 317 to 242 microm (P = .00016). Mean OCT macular volume decreased from 7.89 to 6.80 mm3 (P = .00019). After two injections (n = 12), mean OCT central foveal thickness decreased from 310 to 248 microm following the second injection (P = .04). Mean OCT macular volume decreased from 7.80 to 6.43 mm3 at 1-month follow-up after a second injection (P = .006). There was no significant change in visual acuity after injections.
  
  
  CONCLUSIONS
  In the short-term, ranibizumab decreases the leakage associated with choroidal neovascularization in chronic macular degeneration.
authors.affiliation: Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Fatima K
authors.initials: FK
authors.lastname: Ahmad
authors.forename: Michael G
authors.initials: MG
authors.lastname: Morley
authors.forename: Anna
authors.initials: A
authors.lastname: Berry
authors.forename: Torsten W
authors.initials: TW
authors.lastname: Wiegand
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Heier
authors.forename: Eleanor F
authors.initials: EF
authors.lastname: Morley
authors.forename: Thuss
authors.initials: T
authors.lastname: Sanguansak
authors.forename: Trexler M
authors.initials: TM
authors.lastname: Topping
authors.forename: Albert R
authors.initials: AR
authors.lastname: Frederick
authors.forename: Delia N
authors.initials: DN
authors.lastname: Sang
authors.forename: Mark S
authors.initials: MS
authors.lastname: Hughes
authors.forename: Tina S
authors.initials: TS
authors.lastname: Cleary
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D005122:Exudates and Transudates; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab